Current and Future Treatment Options for Metastatic Renal Cell Carcinoma

European Urology, Supplements

Volumn 8, Issue 10, 2009, Pages 799-808

  Bracarda, Sergio ^a   Ravaud, Alain ^b,c  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b HÔPITAL SAINT ANDRÉ   (France)

^c Centre of Clinical Investigation Clinical Epidemiology   (France)

Author keywords

Everolimus; Immunotherapy; Metastatic renal cell carcinoma; mTOR inhibitors; VEGF targeted therapy

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

ANEMIA; ANOREXIA; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL THERAPY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPHOCYTOPENIA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; PAIN; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; STOMATITIS; TREATMENT FAILURE;

EID: 70349312355     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.08.002     Document Type: Review

References (84)

1. Athar U., and Gentile T.C. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 15 (2008) 3954-3966
2. Gupta K., Miller J.D., Li J.Z., Russell M.W., and Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34 (2008) 193-205
3. Guida M., and Colucci G. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet?. Ann Oncol 18 Suppl 6 (2007) vi149-vi152
4. Kruck S., Kuczyk M.A., Gakis G., Kramer M.W., Stenzl A., and Merseburger A.S. Novel therapeutic options in metastatic renal cancer-review and post ASCO 2007 update. Rev Recent Clin Trials 3 (2008) 212-216
5. van Spronsen D.J., Mulders P.F., and De Mulder P.H. Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol 55 (2005) 177-191
6. Glaspy J.A. Therapeutic options in the management of renal cell carcinoma. Semin Oncol 29 (2002) 41-46
7. Campbell S.C., Flanigan R.C., and Clark J.I. Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol 4 (2003) 363-372
8. Goldman F.D., Dayton P.D., and Hanson C.J. Renal cell carcinoma and osseous metastases. Case report and literature review. J Am Podiatr Med Assoc 79 (1989) 618-625
9. de Riese W., Goldenberg K., Allhoff E., et al. Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence. Int Urol Nephrol 23 (1991) 13-25
10. van Poppel H., and Baert L. Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Acta Urol Belg 64 (1996) 11-17
11. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
12. Mickisch G.H., Garin A., van Poppel H., de Prijck L., and Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (2001) 966-970
13. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., van Poppel H., and Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071-1076
14. Kavolius J.P., Mastorakos D.P., Pavlovich C., Russo P., Burt M.E., and Brady M.S. Resection of metastatic renal cell carcinoma. J Clin Oncol 16 (1998) 2261-2266
15. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163 (2000) 408-417
16. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Guidelines on renal cell carcinoma. European Association of Urology Web site. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/RCC.pdf. Accessed June 2009.
17. Ranieri E., Gigante M., Storkus W.J., and Gesualdo L. Translational mini-review series on vaccines: dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 147 (2007) 395-400
18. Griffiths T.R., and Mellon J.K. Evolving immunotherapeutic strategies in bladder and renal cancer. Postgrad Med J 80 (2004) 320-327
19. Berntsen A., Geertsen P.F., and Svane I.M. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 50 (2006) 34-43
20. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005:CD001425.
21. Yang J.C., and Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 24 (2006) 5576-5583
22. Parton M., Gore M., and Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 24 (2006) 5584-5592
23. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338 (1998) 1272-1278
24. Negrier S. Cytokines in metastatic renal cell carcinoma: conclusions from the French PERCY program. Ann Oncol 17 (2006) ix32-3
25. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110 (2007) 2468-2477
26. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
27. Leibovich B.C., Sheinin Y., Lohse C.M., et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 25 (2007) 4757-4764
28. Patard J.J., Fergelot P., Karakiewicz P.I., et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 123 (2008) 395-400
29. Geertsen P.F., Gore M.E., Negrier S., Tourani J.M., and von der M.H. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer 90 (2004) 1156-1162
30. Bracarda S. Metastatic renal cell carcinoma: pathogenesis and the current medical landscape. Eur Urol Suppl 56 (2009) 787-792
31. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
32. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009) 3584-3590
33. Figlin R.A., Hutson T.E., Tomczak P., et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 26 (2008) abstract 5024
34. Escudier B., Szczylik C., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009) 1280-1289
35. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
36. Bukowski R.M., Eisen T., Szczylik C., et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25 (2007) abstract 5023
37. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27 (2009) 3312-3318
38. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26 (2008) 5422-5428
39. Rini B.I., Halabi S., Rosenberg J., et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206 [abstract]. J Clin Oncol 27 June 20 Suppl (2009) LBA5019
40. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
41. Escudier B.J., Bellmunt J., Negrier S., et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 27 (2009) abstract 5020
42. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
43. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
44. Escudier B., Ravaud A., Oudard S., et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma [abstract 72]. Ann Oncol 19 (2008) viii45
45. Motzer R, Kay A, Figlin R, et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC) [abstract 278]. American Society of Clinical Oncology Web site. http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=64&sessionID=11. Accessed June 2009.
46. Jac J., Amato R.J., Giessinger S., Saxena S., and Willis J.P. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. J Clin Oncol 26 (2008) abstract 5113
47. NCCN clinical practice guidelines in oncology: kidney cancer. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 2009.
48. Escudier B., and Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4 (2009) iv81-iv82
49. de Reijke T.M., Bellmunt J., van Poppel H., Marreaud S., and Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 45 (2009) 765-773
50. Bellmunt J., Calvo E., Castellano D., et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol 63 Suppl 1 (2009) S1-13
51. George D.J., Michaelson M.D., Rosenberg J.E., et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. J Clin Oncol 25 (2007) abstract 5035
52. Dutcher J.P., Wilding G., Hudes G.R., et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol 26 (2008) abstract 5127
53. Axitinib (Ag 013736) as second line therapy for metastatic renal cell cancer: Axis trial (NCT00678392). ClinicalTrials Web site. http://clinicaltrials.gov/ct2/show/NCT00678392?term=nct00678392&recr=Open&rank=1. Accessed June 2009.
54. Sternberg C.N., Szczylik C., Lee E., et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 27 (2009) abstract 5021
55. Shepard D.R., Rini B.I., Garcia J.A., et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 26 (2008) abstract 5123
56. Sablin M.P., Bouaita L., Balleyguier C., et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. J Clin Oncol 25 (2007) abstract 5038
57. Tamaskar I., Garcia J.A., Elson P., et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179 (2008) 81-86
58. Rini B.I., McDermott D., and Atkins M. What is standard initial systemic therapy in metastatic renal cell carcinoma?. Clin Genitourin Cancer 5 (2007) 256-263
59. Sosman J.A., Puzanov I., and Atkins M.B. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 13 (2007) 764s-769s
60. Gollob J.A., Rathmell W.K., Richmond T.M., et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25 (2007) 3288-3295
61. Ryan C.W., Goldman B.H., Lara Jr. P.N., et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25 (2007) 3296-3301
62. Bracarda S., Porta C., Boni C., et al. Sorafenib plus interferon-a2A in metastatic renal cell carcinoma: results from RAPSODY (GOIRC study 0681), a randomized prospective phase II trial of two different treatment schedules. Eur Urol Suppl 7 (2008) 245
63. Sosman J.A., Flaherty K.T., Atkins M.B., et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 26 (2008) abstract 5011
64. The BeST trial: a randomized phase II study of VEGF, Raf kinase, and mTOR combination targeted therapy (CTT) with bevacizumab, sorafenib and temsirolimus in advanced renal cell carcinoma [BeST] [identifier: NCT00378703]. ClinicalTrials Web site. http://clinicaltrials.gov/ct2/show/NCT00378703?term=NCT00378703&rank=1. Accessed June 2009.
65. Whorf R.C., Hainsworth J.D., Spigel D.R., et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 26 (2008) abstract 5010
66. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab in adult patients with kidney cancer (L2201). ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00719264?term=bevacizumab+everolimus&rank=4. Accessed June 2009.
67. Merchan J.R., Liu G., Fitch T., et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 25 (2007) abstract 5034
68. Lam J.S., Leppert J.T., Belldegrun A.S., and Figlin R.A. Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU Int 96 (2005) 483-488
69. Doehn C., Merseburger A.S., Jocham D., and Kuczyk M.A. Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?. Urologe A 46 (2007) 1371-1378
70. Messing E.M., Manola J., Wilding G., et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21 (2003) 1214-1222
71. Clark J.I., Atkins M.B., Urba W.J., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21 (2003) 3133-3140
72. Migliari R., Muscas G., Solinas A., et al. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?. J Chemother 7 (1995) 240-245
73. Pizzocaro G., Piva L., Colavita M., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19 (2001) 425-431
74. Sunitinib treatment of renal adjuvant cancer (S-TRAC): a randomized double blind phase 3 study of adjuvant sunitinib vs. placebo in subjects at high risk of recurrent RCC [identifier: NCT00375674]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00375674. Accessed June 2009.
75. ASSURE: adjuvant sorafenib or sunitinib for unfavorable renal carcinoma [identifier: NCT00326898]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00326898. Accessed June 2009.
76. SORCE: a phase III randomised double-blind study comparing sorafenib with placebo in patients with resected primary renal cell carcinoma at high or intermediate risk of relapse [identifier: NCT00492258]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00492258?term=nct00492258&rank=1. Accessed June 2009.
77. Wood C.G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 13 (2007) 697s-702s
78. Robert G., Gabbay G., Bram R., et al. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 55 (2009) 1477-1480
79. Bex A., Kerst M., Mallo H., Meinhardt W., Horenblas S., and de Gast G.C. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur Urol 49 (2006) 76-81
80. Bex A., Horenblas S., and de Gast G.C. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma. Technol Cancer Res Treat 2 (2003) 205-210
81. Amin C., Wallen E., Pruthi R.S., Calvo B.F., Godley P.A., and Rathmell W.K. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72 (2008) 864-868
82. Ferriere J.M., Wallerand H., Bernhard J.C., Cornu J.N., Roupret M., and Ravaud A. The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies. Prog Urol 18 Suppl 4 (2008) S88-91
83. Thomas A.A., Rini B.I., Lane B.R., et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181 (2009) 518-523
84. Rixe O., Bukowski R.M., Michaelson M.D., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8 (2007) 975-984